Led · Series A · May 2019

Mightier offers a clinically validated at-home video game system that pairs games with biofeedback and evidence-based coping strategies to help children build emotional resilience. The technology was developed by clinicians at Boston Children’s Hospital and Harvard Medical School and is led by CEO Craig Lund. Since launching in 2018, Mightier has helped over 50,000 families, addressing issues such as anxiety, tantrums, ADHD, ODD and ASD. The company plans to use new funding to expand its team and scale its technology to reach more children. It also intends to push further into the healthcare industry via a strategic partnership. Financially, Mightier has raised a total of $29M to date. Mightier is a Boston-based video games program developed and tested at Boston Children’s Hospital and Harvard Medical School that helps children aged 6–14 cope with emotional regulation issues including ADHD, anxiety and anger. Its games use a heart rate monitor so kids can see what they are feeling in real time and practice regulation skills. The current library comprises 25 games and the app has been used to play more than 2.5 million games. Three clinical trials conducted with Boston Children’s Hospital and Harvard Medical School showed that after 12 weeks on the platform children manage their emotions better and parents report less stress. Led by co-founder and CEO Craig Lund, the company raised USD$250k in funding. Mightier intends to use the funds to expand operations and broaden its business reach. Mightier, founded in 2016 out of Boston Children’s Hospital, offers a library of 25 bioresponsive video games designed to treat behaviors associated with emotional dysregulation in kids aged 6–14. The company partners with video game developers and adds a Mightier emotional-learning layer to keep children engaged while teaching regulation skills. Commercially launched in July 2017, Mightier delivers its product via an app (iPhone and Android) paired with a heart-rate monitor and clinician coaching. It offers a starter plan (monitor, app, introductory coaching, progress tracking, parent resources and a private community) and a foundation plan (dedicated tablet, whole-family access and monthly licensed-clinician coaching). To date more than 2.5 million games have been played on the Mightier app. After the Series A, the company has raised over $10.1M and intends to use the new funds to grow product, marketing and engineering teams and to invest in consumer acquisition and engagement strategies. Mightier develops bioresponsive video games and a wearable heart-rate monitor (the Mighty Band) that teach children emotional regulation by making games respond to changes in heart rate. Its product includes the Mighty Band, the Mightier app and game library, six 30-minute coaching sessions, an online hub to track progress, and a private parent community. The company’s current library contains 15 games and it works with external video-game developers to expand offerings. Developed and tested over seven years at Boston Children’s Hospital and Harvard Medical School, Mightier commercially launched in July 2017. The company plans to use the new funding to quadruple its team, expand the game library from 15 to more than 25 titles, and conduct additional clinical research at Massachusetts General Hospital.

Participated · Series B · Jun 2018

WindMIL Therapeutics is a clinical-stage company developing Marrow-Infiltrating Lymphocytes (MILs™) as cancer immunotherapies. The company's founders, Ivan Borrello, M.D., and Kim Noonan, Ph.D., developed a rapid process to extract, activate and expand bone marrow–derived memory T cells to create MILs™. WindMIL's lead program is in a Phase 2 multi-center randomized investigator-sponsored trial in high-risk multiple myeloma, and the company plans to begin clinical trials in solid tumors. Preclinical data indicate MILs™ may serve as a superior cell source for next-generation CAR-T therapies, and WindMIL is exploring proprietary gene modifications to counteract immunosuppressive tumor microenvironments. WindMIL recently completed a $32.5 million Series B financing led by Qiming Venture Partners USA to support development of both unmodified and genetically modified MILs™. The financing also involved new investors Medivate Partners and Camden Partners Nexus, with participation from existing investors Domain Associates and FOXKISER.

Participated · Series C · Jan 2015

Regenxbio is a Rockville, Maryland–based gene therapy-focused biotech leveraging its proprietary NAV® Technology to develop AAV-based treatments for CNS and retinal diseases, including Hurler Syndrome (MPS I), Hunter Syndrome (MPS II) and wet age-related macular degeneration. Led by President and CEO Ken Mills, the company is advancing its lead programs through clinical development and has granted 16 commercial licenses for NAV Technology-based treatments. Regenxbio intends to use new funds to advance lead programs through clinical development, build out clinical and manufacturing infrastructure, expand its team and add to its pipeline of innovative AAV gene therapies. The company closed a $70.5M Series D round that brought total funding to more than $110M. In conjunction with the financing, Dr. Edgar Engleman, Managing Partner of Vivo Capital, joined Regenxbio’s board of directors. Regenxbio leverages its proprietary NAV® Technology to develop gene therapies targeting central nervous system diseases such as Hurler Syndrome (MPS I) and Hunter Syndrome (MPS II). The company is advancing lead programs through clinical development and has plans to build out clinical and manufacturing infrastructure while expanding its team. Regenxbio formed Dimension Therapeutics with Fidelity Biosciences to focus on NAV-based gene therapies for liver-directed rare diseases. Led by President and CEO Ken Mills, the company is positioning its platform to address multiple diseases where gene therapy can make a meaningful difference. Regenxbio is headquartered in Washington, DC. The company completed a financing to support these development and infrastructure goals.